| Market Cap | 2.18M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -5.88M | Forward P/E | -0.78 | EPS next Y | - | 50D Avg Chg | -65.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -11.00% |
| Dividend | N/A | Price/Book | 0.15 | EPS next 5Y | 20.00% | 52W High Chg | -81.00% |
| Recommedations | 2.00 | Quick Ratio | 6.41 | Shares Outstanding | 1.51M | 52W Low Chg | 266.00% |
| Insider Own | 1.29% | ROA | -29.31% | Shares Float | 513.95K | Beta | 0.68 |
| Inst Own | 2.31% | ROE | -52.67% | Shares Shorted/Prior | 31.16K/1K | Price | 1.06 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 467,477 | Target Price | 12.00 |
| Oper. Margin | - | Earnings Date | Nov 20 | Volume | 65,891 | Change | -1.85% |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.